Form 4 for IMNM Immunome Inc.
Accepted 2024-09-20 00:00:00 ET · period of report 2024-09-19 · accession 0001415889-24-023809 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-20 | 2024-09-19 | IMNM | Rosett Max | CFO | S - Sale+OE | $16.01 | -14.4K | 47.5K | -23% | -$230.2K |
| D | 2024-09-20 | 2024-09-19 | IMNM | Rosett Max | CFO | M - OptEx | $1.05 | +42.0K | 61.9K | +212% | +$44.1K |
| D | 2024-09-20 | 2024-09-19 | IMNM | Rosett Max | CFO | M - OptEx | $0.00 | -42.0K | 91.8K | -31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-19 | S | D | 14,380 | $16.01 | 47,476 | D | — | — | (F2) The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-09-19 | M | A | 42,000 | $1.05 | 61,856 | D | — | — | |
| 3 | Derivative | Stock option (right to buy) | 2024-09-19 | M | D | 42,000 | $0.00 | 91,848 | D | $1.05 · — to 2033-03-22 | 42,000 Common Stock | (F3) The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05. (F4) 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter. |